Digital Health: Being a part of health regime, digital health has gained grounds with wireless revolution. Smartphones proved to be the most convenient way as a mode of connection between health care providers and healthcare services. These gadgets will be the smartest way to provide assistance and direct users on their health and wellbeing. New scientific technologies for detecting diseases at an early stage are continuously developing which will encourage customers to take up digital health technology in the long run.

Healthcare reform in Europe: Debt crisis in Europe will curtail its access to benefit based on established rights which might put additional pressures on European government to upset healthcare spending. Chances of political turmoil and price rise for value-based pricing of pharmaceuticals drugs is likely to happen.

Biosimilars: With the advancement of biosimilars, more pharmaceutical companies and generic drug makers will approach to get hold of the landscape. More biotech companies will achieve acquisition in the fore front. In the global market environment both branded generics and branded biosimilars will play a pivotal role. Bio-betters the new player in the biological market will open up a new competition with existing biologics.

Agricultural biotech: New improvements in agricultural biotech are expected to improve crop yield seed and growing more food. Adoption of genetically modified crops and permits on their usage has created new ways for meeting global needs for food and energy. In the year 2011, more than a dozen research agreements with biotechs are involved into agribusiness to generate better crop yields. More on the potential use of biotechnology, China is set to approve biotech rice for planting while India will adopt genetically engineered rice field trials in the near future. Europe will shortly cultivate biotech crops.

Biofuels and biochemicals: Biotech companies are looking forward for an access to capital in order to stay up with research and development facilities. It is expected that the revenues will escalate to pull in more funds in return. 7 bioindustrial companies raised $929 billion in initial public offerings in 2011, with three U.S. IPOs netting $500 million.

Biorenewables: There will be a major thrust in bringing in biochemicals and bioplastics into the industrial market.